Author of

• 20171

  +

  P2.07 - Immunology and Immunotherapy (ID 708)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Immunology and Immunotherapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 23376

    +

    P2.07-001 - Clinicopathological Characteristics of NSCLC Patients with Nivolumab-Induced Pneumonitis (ID 7304)

    09:30 - 09:30  |  Presenting Author(s): Nobuyuki Koyama
    • Abstract

    Background:
    Nivolumab, an immune checkpoint inhibitor, exerts anti-tumor effects against various types of malignant tumor, whereas all usual care should be taken to its related adverse events including immune-related adverse events (irAEs). Of these events, nivolumab-induced pneumonitis, which infrequently develops but sometimes results in a fatal outcome, requires an early detection and prompt response. The purpose of this study was to understand the pathogenesis of nivolumab-induced pneumonitis, leading to avoiding its onset and increase in severity.
    
    Method:
    We retrospectively compared the clinicopathological characteristics between patients with malignant melanoma (M; n = 2) and those with non-small cell lung cancer (NSCLC) (L; n = 2), all of whom developed nivolumab-induced pneumonitis in Tokyo Medical University Hachioji Medical Center.
    
    Result:
    The patients with a median age of 64.5 years (L; 52 years: M, 73 years) were all males, and all NSCLCs consisted of adenocarcinoma histology. The median time from diagnosis to initiation of nivolumab treatment was 34.5 months (L; 33 months: M; 43 months), and that from the initiation of nivolumab treatment to the onset of pneumonitis was 15 days (L; 12.5 days: M; 139.5 days). Image findings showed a non-specific interstitial pneumonia (NSIP) pattern ameliorated by only treatment cessation in one patient with malignant melanoma and organizing pneumonia (OP) patterns that improved with corticosteroids and oxygen inhalation in other three patients. The median survival time from the initiation of nivolumab treatment was 165 days (L; 140.5 days: M; 489 days), and one patient with malignant melanoma who developed the pneumonitis 262 days after nivolumab treatment was successfully retreated with nivolumab.
    
    Conclusion:
    Nivolumab had a high incidence of drug-induced pneumonitis, which consisted mostly of OP patterns highly responsive to corticosteroids. Particular attention should be paid to an early onset after the initiation of treatment.